{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:10:18Z","timestamp":1734048618415,"version":"3.30.2"},"reference-count":59,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.acuroe.2024.10.005","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T19:35:35Z","timestamp":1730403335000},"page":"703-717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing triple therapy in patients with metastatic hormone-sensitive prostate cancer"],"prefix":"10.1016","volume":"48","author":[{"given":"A.","family":"Borque-Fernando","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.A.","family":"P\u00e9rez-Fentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rodrigo-Aliaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Puente-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"G\u00f3mez-Iturriaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Unda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Calleja-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"C\u00f3zar-Olmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"\u00c1lvarez-Ossorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuroe.2024.10.005_bib0005","unstructured":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica (SEOM). Las cifras del c\u00e1ncer en Espa\u00f1a 2023. Accessed January 14, 2024. Available from: https:\/\/seom.org\/images\/Las_cifras_del_Cancer_en_Espana_2023.pdf."},{"key":"10.1016\/j.acuroe.2024.10.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101194","article-title":"Systemic treatment of metastatic hormone-sensitive prostate cancer\u2014upfront triplet versus doublet combination therapy","volume":"8","author":"Oing","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0015","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrclinonc.2014.68","article-title":"High-risk prostate cancer-classification and therapy","volume":"11","author":"Chang","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0020","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0025","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","article-title":"Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies","volume":"73","author":"Gravis","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0030","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.3390\/curroncol30040332","article-title":"Triplet therapy in metastatic castrate sensitive prostate cancer (mCSPC)\u2014a potential new standard of care","volume":"30","author":"Mittal","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0035","unstructured":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer 2024. Accessed May 22, 2024. Available from: https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2024_2024-04-09-132035_ypmy_2024-04-16-122605_lqpk.pdf."},{"key":"10.1016\/j.acuroe.2024.10.005_bib0040","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0045","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0050","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0055","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0060","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0070","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0075","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0080","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0085","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0090","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0095","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0100","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2022.08.002","article-title":"Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"82","author":"Yanagisawa","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0105","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ejca.2022.07.011","article-title":"Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: a meta-analysis","volume":"173","author":"Ciccarese","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100575","article-title":"Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"7","author":"Maiorano","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0115","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2022.40.6_suppl.136","article-title":"Triplet therapy in metastatic castration-sensitive prostate cancer: a systematic review and meta-analysis","volume":"40 Suppl","author":"Naqvi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0120","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.3390\/curroncol29120747","article-title":"Addition of new androgen receptor pathway inhibitors to docetaxel and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: a systematic review and metanalysis","volume":"29","author":"Fiorica","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0125","article-title":"Comparison of doublet and triplet therapies for metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0130","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.euo.2022.06.003","article-title":"Addition of docetaxel to androgen receptor axis\u2013targeted therapy and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: a network meta-analysis","volume":"5","author":"Roy","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0135","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102441","article-title":"Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis","volume":"110","author":"Fallara","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0145","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.euf.2022.08.007","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: a systematic review and network meta-analysis","volume":"9","author":"Mandel","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0150","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.acuro.2022.12.004","article-title":"Consenso multidisciplinar sobre idoneidad farmacol\u00f3gica en c\u00e1ncer de pr\u00f3stata hormono-sensible metast\u00e1sico","volume":"47","author":"Borque-Fernando","year":"2023","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0155","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer\u2014metastatic and\/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Euro J Cancer"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0160","unstructured":"Asociaci\u00f3n Espa\u00f1ola de Urolog\u00eda. Accessed February 22, 2024. Available from: https:\/\/www.aeu.es\/."},{"key":"10.1016\/j.acuroe.2024.10.005_bib0165","unstructured":"SEOM. Informe SEOM de evaluaci\u00f3n de darolutamida en combinaci\u00f3n con docetaxel y terapia de privaci\u00f3n androg\u00e9nica en pacientes con c\u00e1ncer de pr\u00f3stata hormono-sensible metast\u00e1sico (CPHSm). Available from: https:\/\/seom.org\/seomcms\/images\/stories\/Informes_SEOM\/IEV_Darolutamida_metastasico_+_docetaxel.pdf."},{"key":"10.1016\/j.acuroe.2024.10.005_bib0170","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0175","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1200\/JCO.23.00155","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update","volume":"41","author":"Virgo","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0180","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Prostate Cancer Version 4.2024 \u2014 May 17, 2024. Accessed May 22, 2024. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"10.1016\/j.acuroe.2024.10.005_bib0185","unstructured":"Advanced Prostate Cancer: AUA\/SUO Guideline - American Urological Association. Accessed September 7, 2023. Available from: https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/advanced-prostate-cancer."},{"key":"10.1016\/j.acuroe.2024.10.005_bib0190","unstructured":"Ministerio de Sanidad - Profesionales de la Salud - Buscador situaci\u00f3n financiaci\u00f3n medicamentos. Accessed May 22, 2024. Available from: https:\/\/www.sanidad.gob.es\/gl\/profesionales\/medicamentos.do."},{"key":"10.1016\/j.acuroe.2024.10.005_bib0195","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0200","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2023.41.6_suppl.20","volume":"41 Suppl","author":"Mourey","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0205","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0210","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0215","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.eururo.2020.03.019","article-title":"Effect of enzalutamide plus androgen deprivation therapy on health-related quality of life in patients with metastatic hormone-sensitive prostate cancer: an analysis of the ARCHES randomised, placebo-controlled, phase 3 study","volume":"78","author":"Stenzl","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0220","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1200\/JCO.2020.38.6_suppl.87","article-title":"Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: outcomes in patients (pts) with low- and high-risk disease","volume":"38 Suppl","author":"Ozguroglu","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0225","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0230","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0235","article-title":"Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): results of PEACE-1, a phase 3 randomized trial with a 2x2 design","volume":"41 Suppl","author":"Bossi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0240","unstructured":"EAU 2024: State-of-the-Art Lecture: Local Therapy in mHSPC: Who Does Really Benefit? Accessed May 23, 2024. Available from: https:\/\/www.urotoday.com\/conference-highlights\/eau-2024\/eau-2024-prostate-cancer\/151130-eau-2024-state-of-the-art-lecture-local-therapy-in-mhspc-who-does-really-benefit.html."},{"key":"10.1016\/j.acuroe.2024.10.005_bib0245","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.955925","article-title":"Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis","volume":"13","author":"Jian","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0250","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.euo.2023.01.001","article-title":"Adverse events and androgen receptor signaling inhibitors in the treatment of prostate cancer: a systematic review and multivariate network meta-analysis","volume":"6","author":"Cao","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0255","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1007\/s00432-023-04658-6","article-title":"Based on ARASENS trial: efficacy and safety of darolutamide as an emerging option of endocrinotherapy for metastatic hormone-sensitive prostate cancer\u2014an updated systematic review and network meta-analysis","volume":"149","author":"Dou","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0260","unstructured":"Ministerio de Sanidad. BIFIMED. Abiraterona. Accessed May 14, 2024. Available from: https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do?metodo=buscarMedicamentos."},{"key":"10.1016\/j.acuroe.2024.10.005_bib0265","unstructured":"Ministerio de Sanidad. BIFIMED. Apalutamida. Accessed May 14, 2024. Available from: https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do?metodo=verDetalle&cn=724602."},{"key":"10.1016\/j.acuroe.2024.10.005_bib0270","unstructured":"Ministerio de Sanidad. BIFIMED. Darolutamida. Accessed May 14, 2024. Available from: https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do?metodo=verDetalle&cn=728305."},{"key":"10.1016\/j.acuroe.2024.10.005_bib0275","unstructured":"Ministerio de Sanidad. BIFIMED. Enzalutamida. Accessed May 14, 2024. Available from: https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do?metodo=buscarMedicamentos."},{"key":"10.1016\/j.acuroe.2024.10.005_bib0280","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"Vale","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0285","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0290","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/jamaoncol.2021.3987","article-title":"Prognosis associated with luminal and basal subtypes of metastatic prostate cancer","volume":"7","author":"Aggarwal","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.acuroe.2024.10.005_bib0295","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390166","article-title":"Metastatic hormone-sensitive prostate cancer: toward an era of adaptive and personalized treatment","author":"Hamid","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578624001185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578624001185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T23:39:39Z","timestamp":1734046779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578624001185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2173578624001185"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2024.10.005","relation":{},"ISSN":["2173-5786"],"issn-type":[{"type":"print","value":"2173-5786"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing triple therapy in patients with metastatic hormone-sensitive prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2024.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2024.07.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}